Mike Vrabel Becomes 16th Head Coach of the Patriots: What's Next for New England?
New England Patriots appoint Mike Vrabel as head coach after a challenging season under Jerod Mayo. Vrabel, a former Patriots ...
Armed robbery in Revesby1d
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
BioSpace2d
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Pfizer announces ‘positive’ results from Phase 3 CREST trial of sasanlimab
Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...
Joplin Globe2d
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...
Science Daily3d
Milestone in the field of lung transplantation: Improvement in rejection and infection rate thanks to extracorporeal photopheresis
Researchers have published a prospective, randomized and controlled study on the use of extracorporeal photopheresis (ECP) in lung transplantation. The findings could significantly change the standard ...
TMCnet3d
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active ...
Aptose announces first AML patients dosed in TUSCANY trial
Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...
UV light–based cell therapy offers new hope for lung transplant patients, reducing rejection and infection risks
Researchers from the Vienna Lung Transplant Program of MedUni Vienna and University Hospital Vienna have published the first ...
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.